PriceTargets.com logo

Small Pharma - DMT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.15 As of 10/21/2023 12:59 AM ET
▼ -0.01 (-6.25%)

This chart shows the closing price for DMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Small Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMT

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Small Pharma in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.15.

This chart shows the closing price for DMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Small Pharma. This rating has held steady since December 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/16/2023Roth CapitalReiterated RatingBuy
10/18/2022Canaccord Genuity GroupLower TargetC$1.00 ➝ C$0.75
2/4/2022Eight CapitalSet TargetBuyC$1.00
11/8/2021HC WainwrightReiterated RatingBuy
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Small Pharma logo
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc.
Read More

Today's Range

Now: C$0.15
Low: C$0.15
High: C$0.16

50 Day Range

MA: C$0.15
Low: C$0.15
High: C$0.15

52 Week Range

Now: C$0.15
Low: C$0.06
High: C$0.22

Volume

1,890,765 shs

Average Volume

296,159 shs

Market Capitalization

C$50.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Small Pharma?

The following sell-side analysts have issued stock ratings on Small Pharma in the last year:
View the latest analyst ratings for DMT.

What is the current price target for Small Pharma?

0 Wall Street analysts have set twelve-month price targets for Small Pharma in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Small Pharma in the next year.
View the latest price targets for DMT.

What is the current consensus analyst rating for Small Pharma?

Small Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DMT.

What other companies compete with Small Pharma?

Other companies that are similar to Small Pharma include BriaCell Therapeutics, ImmunoPrecise Antibodies, Medicenna Therapeutics, Scythian Biosciences and 138267 (COM.TO). Learn More about companies similar to Small Pharma.

How do I contact Small Pharma's investor relations team?

Small Pharma's physical mailing address is 6-8 Bonhill Street, 3rd Floor, London EC2A 4BX, United Kingdom, . The company's listed phone number is 44 78 1212 1944. The official website for Small Pharma is www.smallpharma.co.uk. Learn More about contacing Small Pharma investor relations.